Analyst Price Targets — ESPR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 24, 2025 10:30 pm | — | Piper Sandler | $9.00 | $3.17 | TheFly | Esperion initiated with an Overweight at Piper Sandler |
| September 25, 2025 6:15 pm | Kristen Kluska | Cantor Fitzgerald | $9.00 | $2.56 | TheFly | Esperion price target raised to $9 from $7 at Cantor Fitzgerald |
| December 17, 2024 11:36 am | Kristen Kluska | Cantor Fitzgerald | $8.00 | $3.04 | TheFly | Esperion initiated with an Overweight at Cantor Fitzgerald |
| May 4, 2022 12:00 am | Serge Belanger | Needham | $12.00 | $6.53 | TipRanks Contributor | Esperion Therapeutics Rises on Upbeat Q1 Results |
| May 4, 2021 12:00 am | Derek Archila | Wells Fargo | $20.00 | $25.59 | Benzinga | Esperion Stock Plummets On Wider Than Expected Q1 Earnings Loss; Analysts Move To Sidelines |
Latest News for ESPR
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Principal Financial Group Inc. lessened its position in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) by 51.7% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm owned 190,056 shares of the biopharmaceutical company's stock after selling 203,234 shares during the quarter. Principal Financial Group
ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m. ET.
ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion against Alkem in response to Alkem's Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of…
Esperion Therapeutics, Inc. (NASDAQ: ESPR - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ESPR.
U.S. House Trading
No House trades found for ESPR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.